Affinia Therapeutics Inc.

Three years after inking a cystic fibrosis collaboration, Boehringer Ingelheim GmbH and its partners are looking to speed up development of what they hope could be a first-in-class gene therapy that

Dyno Therapeutics, Inc. came out of stealth mode a year ago with $9m in seed funding it raised in 2018 and partnerships with Novartis AG and Sarepta Therapeutics, Inc. worth more than $2bn in upf